Category: Press

Contact: Frank DeSanto, Communications Manager, SWOG Cancer Research Network, fdesanto@swog.org, 210.718.2941 Ryan Hohman, JD, Vice President – Public Affairs, Friends of Cancer Research, rhohman@focr.org, 202.944.6708 Ten Years on, Lung-MAP Success Demonstrates Potential of Public-Private Partnerships in Clinical Research The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in…

Contact: Frank DeSanto, Communications Manager, SWOG Cancer Research Network, fdesanto@swog.org, 210.718.2941 Ryan Hohman, JD, Vice President – Public Affairs, Friends of Cancer Research, rhohman@focr.org, 202.944.6708 Lung-MAP Master Protocol Model Broadens Trial Access for Some Underrepresented Groups As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher…

For Immediate Release – ASCO 2022 Abstract #9004 Contact: Frank DeSanto, Communications Manager, SWOG Cancer Research Network, fdesanto@swog.org, 210.718.2941 Ryan Hohman, JD, Vice President – Public Affairs, Friends of Cancer Research, rhohman@focr.org, 202.944.6708 Ramucirumab plus pembrolizumab combination reduced risk of death by 31 percent compared to standard of care in patients with advanced non-small cell lung cancer that had…

For Immediate Release Contact: Wendy Lawton, Communications Manager, SWOG Cancer Research Network, lawtonw@ohsu.edu, 503-348-8675 Ryan Hohman, JD, Vice President – Public Affairs, Friends of Cancer Research, rhohman@focr.og  202.944.6708 Lung-MAP Translational Discoveries Shared at 2020 World Conference on Lung Cancer WASHINGTON, DC – Investigators leading the Lung Cancer Master Protocol, or Lung-MAP trial, will present findings from three translational medicine…

A majority of cancer patients don’t understand key aspects of the genomic test results they receive as participants in biomarker-driven clinical trials, according to a first-of-its-kind pilot study conducted under the Lung Cancer Master Protocol (Lung-MAP). In a September 9 presentation at the World Conference on Lung Cancer in Barcelona, Lung-MAP investigator Joshua A. Roth, PhD,…

For Immediate Release Jan. 29, 2019 Please Contact: Ryan Hohman, Vice President – Public Affairs, Friends of Cancer Research rhohman@focr.org; 202-944-6708 Wendy Lawton, Communications Manager, SWOG lawtonw@ohsu.edu; 503.348.8675 Lung-MAP Precision Medicine Trial Expands To Include More Patients Washington, DC – The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the…

For Immediate Release Feb. 29, 2016 Please Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org Wendy Lawton, Communications and Public Relations Manager, SWOG: 503.348.8675 –lawtonw@ohsu.edu Lung-MAP Precision Medicine Trial Makes Exciting Changes, With New Science and Treatment Options for Patients Lung-MAP, the most collaborative and comprehensive lung cancer clinical…

For Immediate Release Media Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org or Frank DeSanto, Communications Manager, SWOG Cancer Research: 503.348.1710 – desanto@oshu.edu Statement from Lung-MAP Clinical Trial Leadership Regarding FDA Approval of Nivolumab On March 4, 2015, the U.S. Food and Drug Administration (FDA) announced…

For Immediate Release Please Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org or Frank DeSanto, Communications Manager, SWOG Cancer Research: 503.348.1710 – desanto@oshu.edu Innovative Lung-MAP Lung Cancer Trial Open and Enrolling Patients at over 400 Sites in 39 States Trial will Close One of Five Trial…